Decision Resources Research Reports

Title	Published	Price
The Increasing Influence of Payers, Providers, and Patients on the U.S. Pharmaceutical Market By: Decision Resources Pharmaceutical manufacturers must contend with the often-confl icting requirements of three principal customer groups: payers, providers, and patients. Health plans and pharmacy benefi t management companies (PBMs) maintain enormous infl uence over consumers’ health care \| more...	10/29/2007	$1,112.50
How Insulin Resistance Diagnostics Can Expand the Market for Insulin-Sensitizing Agents By: Decision Resources Insulin resistance is a highly prevalent metabolic condition fraught with unmet need. Although several diagnostics are in use, not one is ideal; a standardized, simple tool for measuring IR in clinical practice is needed. Novel \| more...	10/23/2007	$1,112.50
How to Avoid Health Care Rationing: Don't Restrict Supply, Manage Demand By: Decision Resources Is health care the only business where companies and institutions are actively turning away customers rather than fi nding innovative ways to serve them? Health care reform that is aimed at managing demand—as opposed to \| more...	10/18/2007	$1,112.50
Can the Use of Biomarkers as Surrogate End Points Stimulate the Drug-Development Lull By: Decision Resources Biopharmaceutical companies are exploring ways to bring their products to market as quickly and as effi ciently as possible. The use of biomarkers that function as surrogate end points in clinical trials may allow product \| more...	10/12/2007	$1,112.50
Pricing and Reimbursement Issues for Immune Disease Therapies By: Decision Resources Within major international pharmaceutical markets, drug therapies for immune disorders span an enormous price range—from a few cents per day to tens of thousands of dollars per year. Not surprisingly, payers impose restrictions on the \| more...	10/12/2007	$1,112.50
Synthetic Biology: An Emerging Tool for Drug Discovery and Production By: Decision Resources Lying at the interface of biology and engineering, synthetic biology represents a new discipline emphasizing an engineering approach to building biological systems from components. Already, simple synthetic devices such as biological “clocks” have been created \| more...	10/1/2007	$1,112.50
Trends in the Commercialization of Biomarkers: Tests and Companies By: Decision Resources As health care moves toward personalized medicine, biomarkers have gained an increasingly important role in the delivery of efficient, quality care. The FDA has established specific definitions for biomarkers, and diagnostics, biotechnology, and pharmaceutical companies \| more...	10/1/2007	$1,112.50
Paving the Difficult Road to Universal Insurance Coverage: Spotlight on U.S. Innovators By: Decision Resources The controversial issue of establishing universal health insurance has recently reclaimed the spotlight in the United States. Various states, members of Congress, President George W. Bush, and 2008 presidential hopefuls are proposing plans to make \| more...	9/28/2007	$1,112.50
Kick-Starting R&D in India: Challenges and Opportunities By: Decision Resources India’s pharmaceutical market—one of the most developed among emerging nations—has grown healthily over the past seven years. A change in the wealth, living standards, and demographics of the 1 billion people living in India has \| more...	9/24/2007	$1,112.50
Building on Early Successes of Immunomodulators in the Fight Against Cancer By: Decision Resources Although no immunotherapies have yet emerged to fulfill immunologists’ decades-long hope of developing safe, highly effective, tumor-specific immunotherapies, the field of nonspecific immunomodulatory drugs is enjoying modest success. Three established immunomodulatory drugs for cancer achieved \| more...	9/12/2007	$1,112.50
Change Is Percolating Through Japan's Pharmaceutical Markets By: Decision Resources Japan’s pharmaceutical markets are increasingly more competitive, and a steady restructuring of the Japanese pharmaceutical industry is under way. The government continues to tighten its control over drug expenditures, and foreign and multinational pharmaceutical companies \| more...	9/12/2007	$1,112.50
Recent Advances in the Fast-Growing Molecular Diagnostics Industry By: Decision Resources Molecular diagnostics (MDx) is becoming increasingly entwined with the development of pharmaceutical drugs. Initially, it was used in clinical settings to aid diagnosis, prognosis, and optimal treatment, but now, backed by regulatory authorities, it is \| more...	9/12/2007	$1,112.50
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Second Quarter of 2007 By: Decision Resources Following considerable political activity in drug pricing and reimbursement in the world’s major pharmaceutical markets in the fi rst three months of 2007, the second quarter of the year proved to be relatively quiet. In \| more...	9/10/2007	$1,112.50
Evolving Approaches for Protein Drug Delivery By: Decision Resources Despite their remarkable success, protein drugs continue to suffer from important drawbacks, especially with respect to their delivery (subcutaneously or intravenously injected). Improvements in protein drug delivery will increase patient compliance and expand many drug \| more...	8/27/2007	$1,112.50
Does the Treatment of Huntington's Disease Represent a Commercial Opportunity? By: Decision Resources Huntington’s disease (HD) is a genetic neurological disorder characterized by uncontrolled body movements and cognitive dysfunction. No drugs are approved to treat the disorder, leaving a high level of unmet need. Commercial opportunity abounds, but \| more...	8/20/2007	$1,112.50
Pharmaceutical Distribution in Europe: Pfizer Breaks the Mold By: Decision Resources Beginning March 2007, Pfi zer introduced a direct distribution system for its products in the United Kingdom, making them available only from the company’s sole appointed distributor rather than from a choice of wholesalers. This \| more...	8/9/2007	$1,112.50
Challenges for a Maturing Biotechnology Industry: Evolve or Perish By: Decision Resources Today’s biotech industry is maturing and must now change the way it operates. The industry is facing signifi cant challenges from operational, business, clinical development, and market risks. Business fundamentals, which many biotech companies have \| more...	8/1/2007	$1,112.50
Building Better Cancer Vaccines: The Progress and Promise of R&D By: Decision Resources Cancer vaccines are the newest weapon in the battle against cancer. Vaccines promise to boost the body’s natural abilities to halt the progression of the disease. Although standard cancer treatments such as surgery, chemotherapy, and \| more...	7/30/2007	$1,112.50
Creating Win-Win Solutions from the Ongoing Drug Cost and Price Debate By: Decision Resources In 2007, we are approaching a tipping point in the standoff between drug customers/payers and drug producers, each striving to achieve an advantage in the struggle between drug cost versus drug price. The solution to \| more...	7/24/2007	$1,112.50
Blockbuster Patent Expirations and the Future of the Generics Market By: Decision Resources Approximately 90 pharmaceuticals achieved blockbuster status in 2006, generating more than $200 billion in sales—approximately 30% of the global pharmaceutical market. However, in 2007, eight blockbuster brands— with combined 2006 sales of $13 billion in \| more...	6/29/2007	$2,250.00
Novel Approaches to Diagnosing Pulmonary Diseases By: Decision Resources Each of the three broad pulmonary disease areas—infectious respiratory disease, obstructive respiratory disease, and lung cancer—has its favored set of diagnostic methods. However, current methods of diagnosing pulmonary diseases have not fully provided the necessary \| more...	6/26/2007	$1,112.50
How Will Recent Safety Concerns Affect PPAR-Gamma Agonists? By: Decision Resources Introduction The peroxisome proliferator-activated receptor (PPAR)-gamma agonist class of drugs is the fastest-growing drug class in the type 2 diabetes market. Sales of the two PPAR-gamma agonists, GlaxoSmithKline’s Avandia and Takeda’s Actos, are signifi cant \| more...	6/25/2007	$1,112.50
State Activities: Impact on the U.S. Pharmaceutical Industry By: Decision Resources Introduction In 2005, 17% of the nation’s $2 trillion in health care costs was paid by state and local governments, including more than $21.7 billion for prescription drugs; these costs are expected to double over \| more...	6/25/2007	$1,112.50
Practical Defense Strategies for Combating Generics Competition By: Decision Resources Introduction Can branded pharmaceutical companies ever win the war against generics? No. But they can win some of the battles. Growing pressures on innovator companies means that innovator companies are becoming more inventive in searching \| more...	6/21/2007	$1,112.50
Pharmaceutical Innovation: Is It Really Rewarded? By: Decision Resources Introduction Governments in the world’s largest pharmaceutical markets clearly have an interest in promoting access to innovative medicines, but the relatively high price of many novel drugs can place a heavy fi nancial burden on \| more...	6/15/2007	$1,112.50
Title	Published	Price

< prev 1 2 3 4 5 6 7 8 9 10 next >

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/24/2009 - 4